TCGA-AC-A6IX-06A-11R-A32P-07
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
- overall_survival_months
- 12
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.410
- IL6_JAK_STAT3_SIGNALING+0.290
- FATTY_ACID_METABOLISM+0.210
- INTERFERON_GAMMA_RESPONSE+0.200
- KRAS_SIGNALING_UP+0.200
- PI3K_AKT_MTOR_SIGNALING+0.200
- INTERFERON_ALPHA_RESPONSE+0.190
- INFLAMMATORY_RESPONSE+0.130
- P53_PATHWAY+0.120
- PROTEIN_SECRETION+0.120
Top 10 suppressed
- G2M_CHECKPOINT-0.560
- E2F_TARGETS-0.520
- MYC_TARGETS_V2-0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.490
- MYC_TARGETS_V1-0.460
- MTORC1_SIGNALING-0.350
- TGF_BETA_SIGNALING-0.340
- GLYCOLYSIS-0.290
- MITOTIC_SPINDLE-0.290
- ESTROGEN_RESPONSE_EARLY-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518296 | — | A | 0.837 |
| 2 | SRR33532817 | — | D | 0.816 |
| 3 | SRR13780265 | — | cohortMD2 | 0.816 |
| 4 | TCGA-86-8076-01A-31R-2241-07 | — | cohortA1 | 0.814 |
| 5 | TCGA-97-A4M0-01A-11R-A24X-07 | — | cohortA1 | 0.804 |
| 6 | SRR2932840 | — | — | 0.803 |
| 7 | TCGA-62-A46Y-01A-11R-A24H-07 | — | cohortA1 | 0.803 |
| 8 | SRR8518151 | — | D | 0.794 |
| 9 | SRR12475112 | — | — | 0.792 |
| 10 | TCGA-OR-A5LN-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.792 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.410 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.290 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.190 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.130 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.120 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.120 | Remibrutinib | — uncovered |
| PEROXISOME | 0.110 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.090 | Inavolisib | — uncovered |
| COMPLEMENT | 0.080 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.080 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.050 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.040 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.020 | Remibrutinib | — uncovered |